LRRK2 and Parkinson disease: Experiments on iPSCs expressing different pathogenic mutations in the PD gene, leucine-rich repeat kinase 2 (LRRK2), e.g., p.G2019S, showed disrupted mechanisms including aggregation of α-synuclein, mitochondrial transport, and lysosomal autophagy [77].